These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23251769)

  • 1. Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.
    Cozzolino M; Rizzo MA; Stucchi A; Cusi D; Gallieni M
    Ther Adv Chronic Dis; 2012 Mar; 3(2):59-68. PubMed ID: 23251769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure.
    Spaia S
    Hippokratia; 2011 Jan; 15(Suppl 1):22-6. PubMed ID: 21897754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.
    Lorenzo Sellares V; Torres Ramírez A
    Drugs Aging; 2004; 21(3):153-65. PubMed ID: 14979734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients.
    Ossareh S
    Int J Nephrol Renovasc Dis; 2014; 7():161-8. PubMed ID: 24855385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone health and vascular calcification relationships in chronic kidney disease.
    Spasovski GB
    Int Urol Nephrol; 2007; 39(4):1209-16. PubMed ID: 17899431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
    Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
    PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?
    Cozzolino M; Ureña-Torres P; Vervloet MG; Brandenburg V; Bover J; Goldsmith D; Larsson TE; Massy ZA; Mazzaferro S;
    Nephrol Dial Transplant; 2014 Oct; 29(10):1815-20. PubMed ID: 24516228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
    Ketteler M; Sprague SM; Covic AC; Rastogi A; Spinowitz B; Rakov V; Walpen S; Floege J
    Nephrol Dial Transplant; 2019 Jul; 34(7):1163-1170. PubMed ID: 29846719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects.
    Frazão JM; Adragão T
    Nephron Clin Pract; 2012; 120(2):c108-19. PubMed ID: 22555359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
    Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
    Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
    Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
    J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation.
    Brandenburg VM; Jahnen-Dechent W; Ketteler M
    Kidney Int Suppl; 2009 Dec; (114):S26-33. PubMed ID: 19946324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
    Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
    Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperphosphatemia and phosphate binders: effectiveness and safety.
    Kalaitzidis RG; Elisaf MS
    Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.